Due to its known antiviral activity and its clinical administration in chronic viral infections, IFN-I, specifically IFNα2 or IFNβ, were already used in a variety of different clinical trials in patients with mild or severe COVID-19. This evidence concerns the gene IFNB1 and COVID-19.